Dtsch Med Wochenschr 2014; 139(25/26): 1357-1372
DOI: 10.1055/s-0034-1369993
CME | Review article
Gastroenterologie, Infektiologie
© Georg Thieme Verlag KG Stuttgart · New York

Gastrointestinale Infektionen

Gastrointestinal infections
M. Weber
1   Klinik für Innere Medizin IV (Gastroenterologie, Hepatologie und Infektiologie), Universitätsklinikum Jena der Friedrich-Schiller-Universität Jena
,
S. Hagel
1   Klinik für Innere Medizin IV (Gastroenterologie, Hepatologie und Infektiologie), Universitätsklinikum Jena der Friedrich-Schiller-Universität Jena
2   Zentrum für Infektionsmedizin und Krankenhaushygiene, Universitätsklinikum Jena der Friedrich-Schiller-Universität Jena
3   Center for Sepsis Control and Care (CSCC), Universitätsklinikum Jena der Friedrich-Schiller-Universität Jena
,
A. Stallmach
1   Klinik für Innere Medizin IV (Gastroenterologie, Hepatologie und Infektiologie), Universitätsklinikum Jena der Friedrich-Schiller-Universität Jena
› Author Affiliations
Further Information

Publication History

02 December 2013

31 January 2014

Publication Date:
10 June 2014 (online)

 
  • Literatur

  • 1 Abou Chakra CN, Pepin J, Valiquette L. Prediction tools for unfavourable outcomes in Clostridium difficile infection: a systematic review. PloS one 2012; 7: e30258
  • 2 Avery ME, Snyder JD. Oral therapy for acute diarrhea. The underused simple solution. The New England journal of medicine 1990; 323: 891-894
  • 3 Bauer MP, Hensgens MP, Miller MA et al. Renal failure and leukocytosis are predictors of a complicated course of Clostridium difficile infection if measured on day of diagnosis. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2012; 55 (Suppl. 02) S149-153
  • 4 Ben-Horin S, Margalit M, Bossuyt P et al. Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection. Journal of Crohn's & colitis 2010; 4: 194-198
  • 5 de Wit MA, Hoogenboom-Verdegaal AM, Goosen ES et al. A population-based longitudinal study on the incidence and disease burden of gastroenteritis and Campylobacter and Salmonella infection in four regions of The Netherlands. European journal of epidemiology 2000; 16: 713-718
  • 6 Debast SB, Bauer MP, Kuijper EJ et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): update of the treatment guidance document for Clostridium difficile infection (CDI). Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2013; DOI: 10.1111/1469-0691.12418.
  • 7 Deshpande A, Pasupuleti V, Patel P et al. Repeat stool testing for Clostridium difficile using enzyme immunoassay in patients with inflammatory bowel disease increases diagnostic yield. Current medical research and opinion 2012; 28: 1553-1560
  • 8 Frank C, Werber D, Cramer JP et al. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. The New England journal of medicine 2011; 365: 1771-1780
  • 9 Garg S, Mirza YR, Girotra M et al. Epidemiology of Clostridium difficile-associated disease (CDAD): a shift from hospital-acquired infection to long-term care facility-based infection. Digestive diseases and sciences 2013; 58: 3407-3412
  • 10 Geerdes-Fenge HF, Lobermann M, Nurnberg M et al. Ciprofloxacin reduces the risk of hemolytic uremic syndrome in patients with Escherichia coli O104:H4-associated diarrhea. Infection 2013; 41: 669-673
  • 11 Gerding DN, Muto CA, Owens Jr RC. Measures to control and prevent Clostridium difficile infection. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2008; 46 (Suppl. 01) S43-49
  • 12 Gore JI, Surawicz C. Severe acute diarrhea. Gastroenterology clinics of North America 2003; 32: 1249-1267
  • 13 Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2011; 53: 994-1002
  • 14 Hogenauer C, Langner C, Beubler E et al. Klebsiella oxytoca as a causative organism of antibiotic-associated hemorrhagic colitis. The New England journal of medicine 2006; 355: 2418-2426
  • 15 Holtz LR, Neill MA, Tarr PI. Acute bloody diarrhea: a medical emergency for patients of all ages. Gastroenterology 2009; 136: 1887-1898
  • 16 Ikeda K, Ida O, Kimoto K et al. Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection. Clinical nephrology 1999; 52: 357-362
  • 17 Jansen A, Stark K, Kunkel J et al. Aetiology of community-acquired, acute gastroenteritis in hospitalised adults: a prospective cohort study. BMC infectious diseases 2008; 8: 143
  • 18 Kern WV. [Management of patients with EHEC/HUS. Lessons and perspectives from clinical infectious disease specialists]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2013; 56: 87-94
  • 19 Khanna S, Pardi DS. IBD: Poor outcomes after Clostridium difficile infection in IBD. Nature reviews Gastroenterology & hepatology 2012; 9: 307-308
  • 20 Klein EJ, Boster DR, Stapp JR et al. Diarrhea etiology in a Children's Hospital Emergency Department: a prospective cohort study. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2006; 43: 807-813
  • 21 Kola A. [Clostridium difficile-associated infections. How dangerous are the new strains?]. Der Internist 2010; 51: 154-160
  • 22 Koletzko S, Osterrieder S. Acute infectious diarrhea in children. Deutsches Arzteblatt international 2009; 106: 539-547; quiz 548
  • 23 Lancaster JW, Matthews SJ. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections. Clinical therapeutics 2012; 34: 1-13
  • 24 Lynen Jansen P, Stallmach A, Lohse AW et al. Entwicklung infektiöser Durchfallserkrankungen zwischen den Jahren 2000 und 2012. Zeitschrift fur Gastroenterologie 2014; in press
  • 25 Mattila E, Uusitalo-Seppala R, Wuorela M et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology 2012; 142: 490-496
  • 26 McFarland LV, Mulligan ME, Kwok RY et al. Nosocomial acquisition of Clostridium difficile infection. The New England journal of medicine 1989; 320: 204-210
  • 27 Robert-Koch-Institut. RKI-Ratgeber für Ärzte: Erkrankungen durch Enterohämorrhagische Escherichia coli (EHEC).
  • 28 Robert-Koch-Institut. Bericht: Abschließende Darstellung und Bewertung der epidemiologischen Erkenntnisse im EHEC O104:H4 Ausbruch.
  • 29 Safdar N, Said A, Gangnon RE et al. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. JAMA: the journal of the American Medical Association 2002; 288: 996-1001
  • 30 Schmid D, Kuo HW, Simons E et al. All-cause mortality in hospitalized patients with infectious diarrhea: Clostridium difficile versus other enteric pathogens in Austria from 2008 to 2010. Journal of infection and public health 2013; DOI: 10.1016/j.jiph.2013.07.010.
  • 31 Schmidt C, Köhler S, Kräplin T et al. Does the hospital cost of care differ for inflammatory bowel disease patients with or without gastrointestinal infections? A case-control study. Zeitschrift für Gastroenterologie 2014; in press
  • 32 Schneider T, Eckmanns T, Ignatius R et al. Clostridium-difficile-assoziierte Diarrhö: Ein zunehmendes klinisches Problem durch neue hochvirulente Erreger. Dtsch Arztebl 2007; 104: A-1588 / B-1403 / C-1343
  • 33 Sethi AK, Al-Nassir WN, Nerandzic MM et al. Skin and environmental contamination with vancomycin-resistant Enterococci in patients receiving oral metronidazole or oral vancomycin treatment for Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2010; 30: 13-17
  • 34 Smith KE, Wilker PR, Reiter PL et al. Antibiotic treatment of Escherichia coli O157 infection and the risk of hemolytic uremic syndrome, Minnesota. The Pediatric infectious disease journal 2012; 31: 37-41
  • 35 Stallmach A, Carstens O. Role of infections in the manifestation or reactivation of inflammatory bowel diseases. Inflammatory bowel diseases 2002; 8: 213-218
  • 36 Vallieres E, Saint-Jean M, Rallu F. Comparison of three different methods for detection of Shiga toxin-producing Escherichia coli in a tertiary pediatric care center. Journal of clinical microbiology 2013; 51: 481-486
  • 37 van Nood E, Vrieze A, Nieuwdorp M et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. The New England journal of medicine 2013; 368: 407-415
  • 38 Yakob L, Riley TV, Paterson DL et al. Clostridium difficile exposure as an insidious source of infection in healthcare settings: an epidemiological model. BMC infectious diseases 2013; 13: 376